Semaglutide vs Tirzepatide: Comparing GLP-1 Therapies

The GLP 1 receptor agonist class has fundamentally reshaped how we treat type 2 diabetes and obesity. Two molecules dominate the landscape: semaglutide (Novo Nordisk's Ozempic and Wegovy) and tirzepatide (Eli Lilly's Mounjaro and Zepbound). Both target the GLP 1 receptor, but their pharmacological profiles differ in meaningful ways, and understanding those differences is essential for choosing the right therapy for each patient.

Semaglutide is a selective GLP 1 receptor agonist (Nauck et al., 2022, Cardiovasc Diabetol; PMID: 36050763). It mimics the action of your body's own GLP 1, binding to receptors in the pancreas (where it stimulates glucose dependent insulin secretion), the brain (where it promotes satiety through hypothalamic and brainstem circuits), and the GI tract (where it slows gastric emptying (Drucker, 2018, Cell Metab; PMID: 29617641)). It lasts about a week in the body thanks to a C 18 fatty acid side chain that binds albumin (Lau et al., 2015, Journal of Medicinal Chemistry; PMID: 26308095).

Tirzepatide does something different. It is a dual GIP/GLP 1 receptor agonist, the first approved molecule in this class (Nauck et al., 2022, Cardiovasc Diabetol; PMID: 36050763). On top of GLP 1 receptor activation, tirzepatide also potently activates glucose dependent insulinotropic polypeptide (GIP) receptors (Coskun et al., 2018, Mol Metab; PMID: 30473097). GIP receptor activation may add complementary metabolic effects, such as on insulin secretion and adipose tissue, although how much GIP contributes to tirzepatide's effects in humans is still being studied (Nauck et al., 2022, Cardiovasc Diabetol; PMID: 36050763). The GIP component may also help reduce some of the nausea that comes with pure GLP 1 agonism (Samms et al., 2021, Diabetes; PMID: 34176786).

The STEP and SURMOUNT trial programs provide most of the efficacy data, and the head-to-head SURMOUNT-5 trial has directly compared the two drugs in adults with obesity (Aronne et al., 2025, N Engl J Med; PMID: 40353578). In the STEP 1 trial, semaglutide 2.4 mg (Wegovy) produced a mean weight loss of 14.9% versus 2.4% with placebo over 68 weeks (Wilding et al., 2021, NEJM; PMID: 33567185). The STEP 5 trial showed durability, with participants maintaining a 15.2% weight reduction at 104 weeks (Garvey et al., 2022, Nat Med; PMID: 36216945). Tirzepatide's numbers were even more impressive. In SURMOUNT 1, the highest dose (15 mg) produced a mean weight loss of 20.9% versus 3.1% with placebo over 72 weeks (Jastreboff et al., 2022, NEJM; PMID: 35658024). The 10 mg dose hit 19.5%, and even the lowest 5 mg dose reached 15.0%, which is comparable to semaglutide's maximum dose (Jastreboff et al., 2022, N Engl J Med; PMID: 35658024). Cross trial comparisons always come with caveats (different patient populations, endpoints, and timeframes), but the data consistently suggests tirzepatide produces greater absolute weight loss, likely because of the additive effects of dual agonism (Aronne et al., 2025, N Engl J Med; PMID: 40353578).

Both molecules deliver excellent glycemic control. In the SURPASS 1 to 5 trials, tirzepatide reduced HbA1c by roughly 1.2 to 2.6 percentage points depending on dose and trial (Nauck et al., 2022, Cardiovasc Diabetol; PMID: 36050763)%. Semaglutide in the SUSTAIN trials reduced HbA1c by 1.5 to 1.8 (Meier, 2021, Front Endocrinol (Lausanne); PMID: 34248838)%. The SURPASS 2 trial, which directly compared tirzepatide to semaglutide 1 mg, showed tirzepatide was superior at all doses for both HbA1c reduction and weight loss (Frias et al., 2021, NEJM; PMID: 34170647).

On the cardiovascular front, semaglutide has a clear advantage in terms of proven benefit. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in overweight and obese adults without diabetes (Lincoff et al., 2023, NEJM; PMID: 37952131). That was a landmark finding. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) found it was noninferior to dulaglutide, a GLP-1 receptor agonist with proven cardiovascular benefit, for major adverse cardiovascular events in people with type 2 diabetes and atherosclerotic cardiovascular disease (Nicholls et al., 2025, N Engl J Med; PMID: 41406444). Early metabolic signals are encouraging, but we do not have definitive MACE data yet.

Both molecules share a similar gastrointestinal side effect profile, which comes with the class (Aronne et al., 2025, N Engl J Med; PMID: 40353578). Nausea is the most common side effect of both drugs, and a network meta-analysis of randomized trials found tirzepatide carried the highest relative risk of nausea among the GLP-1-based drugs compared (Joy et al., 2026, Endocrine; PMID: 41489846)). The same analysis found semaglutide carried the highest relative risk of vomiting (Joy et al., 2026, Endocrine; PMID: 41489846). Tirzepatide carried the highest relative risk of diarrhea, while semaglutide carried the highest relative risk of constipation (Joy et al., 2026, Endocrine; PMID: 41489846). The lower nausea and vomiting rates with tirzepatide may be attributable to the GIP component's modulatory effects on the emetic pathway. Both require gradual dose titration over 16 to 20 weeks to minimize GI side effects (Jastreboff et al., 2022, N Engl J Med; PMID: 35658024). Rare but serious risks include pancreatitis, gallbladder disease, and a theoretical concern about medullary thyroid carcinoma based on rodent studies, which led to a boxed warning for the class (Rajan et al., 2026, Eur J Endocrinol; PMID: 42541759)). Neither should be used in patients with a personal or family history of MTC or MEN2 syndrome (Rajan et al., 2026, Eur J Endocrinol; PMID: 42541759).

From a practical standpoint, both are once weekly subcutaneous injections, so convenience is a wash. For weight management, semaglutide is escalated every 4 weeks over 16 weeks to the 2.4 mg maintenance dose (Rubino et al., 2021, JAMA; PMID: 33755728)). Tirzepatide has a similar pattern with a few more intermediate steps (2.5, 5, 7.5, 10, 12.5, then 15 mg), which some clinicians find allows more granular titration (Dahl et al., 2022, JAMA; PMID: 35133415). Both faced shortages driven by high demand, and the FDA has since declared the shortages of both semaglutide and tirzepatide resolved (Trainer, 2026, J Am Assoc Nurse Pract; PMID: 42201545). Insurance coverage varies widely, and prior authorization is common for weight management indications. For compounded versions, providers should stay current on the regulatory status following the FDA's 2024 decisions. The Peptide Association's regulatory updates track this evolving landscape.

So which one should you choose? If cardiovascular risk reduction is a primary goal, semaglutide has established MACE benefit (Lincoff et al., 2023, N Engl J Med; PMID: 37952131). If the patient has a history of GI sensitivity, semaglutide may also be preferable given lower overall discontinuation rates in real world data. If maximum weight loss is the goal, or the patient has significant insulin resistance, tirzepatide's dual mechanism may offer advantages. And if GI tolerability during titration is a concern, tirzepatide's lower nausea rates could tip the balance. Ultimately, both are transformative therapies, and the decision should be individualized based on the patient's metabolic profile, comorbidities, insurance coverage, and treatment goals.